About Tripartite motif-containing protein 77
Tripartite motif-containing protein 77 (TRIM77) is a protein
from Homo sapiens identified by UniProt accession
I1YAP6, 450 residues long.
MolForge cross-references it against 0 known binders and
27 disease associations.
Target properties
| Protein name | Tripartite motif-containing protein 77 |
| UniProt accession | I1YAP6 |
| Gene | TRIM77 |
| Organism | Homo sapiens |
| Length | 450 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (27)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.29
- forced expiratory volume · score 0.11
- lean body mass · score 0.10
- vital capacity · score 0.09
- body height · score 0.08
- hemolytic anemia · score 0.08
- fat body mass · score 0.08
- base metabolic rate measurement · score 0.07
- diabetic retinopathy · score 0.06
- whole body water mass · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-I1YAP6-F1 | alphafold | PREDICTED | 81.58 | — |
Amino-acid sequence (450 residues)
MASAITQCST SELTCSICTD YLTDPVTICC GHRFCSPCLC LLWEDTLTPN CCPVCREISQ QMYFKRIIFA EKQVIPTRES VPCQLSSSAM LICRRHQEIK NLICETDRSL LCFLCSQSPR HATHKHYMTR EADEYYRKKL LIQMKSIWKK KQKNQRNLNR ETNIIGTWEV FINLRSMMIS AEYPKVCQYL REEEQKHVES LAREGRIIFQ QLKRSQTRMA KMGILLREMY EKLKEMSCKA DVNLPQDLGD VMKRNEFLRL AMPQPVNPQL SAWTITGVSE RLNFFRVYIT LDRKICSNHK LLFEDLRHLQ CSLDDTDMSC NPTSTQYTSS WGAQILSSGK HYWEVDVKDS CNWVIGLCRE AWTKRNDMRL DSEGIFLLLC LKVDDHFSLF STSPLLPHYI PRPQGWLGVF LDYECGIVSF VNVAQSSLIC SFLSRIFYFP LRPFICHGSK
Explore Tripartite motif-containing protein 77 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets